Murali Ramachandra

Syngene International (India) — India

Medicine · Health Sciences

33h-index6.7kcitations246works2.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(33), Protein Degradation and Inhibitors(32), Peptidase Inhibition and Analysis(23), Cytokine Signaling Pathways and Interactions(22), Virus-based gene therapy research(20)

Publications243 total

288 Novel IL-15 modules promote long-term persistence, repeated tumor killing and self-sustenance of chimeric antigen receptor-natural killer (CAR-NK) cells manufactured using an indigenous platform
Regular and Young Investigator Award Abstracts·2025Open Access
Abstract A030: Discovery and preclinical characterization of novel macrocyclic KIF18A Inhibitors for treatment of chromosomally instable tumors
Molecular Cancer Therapeutics·2025
Abstract C059: Development of a Differentiated, Best-in-Class Oral Cbl-b Inhibitor with Robust Immune Activation and Favourable Safety for Cancer Immunotherapy
Molecular Cancer Therapeutics·2025
Abstract C025: Identification of an orally bio-available SMARCA2 selective degrader for treatment of SMARCA4 mutant cancers
Molecular Cancer Therapeutics·2025
Abstract B077: Discovery and development of a highly differentiated, efficacious, first-in-class anti-SIRPα/β dual antibody with single agent phagocytosis activity
Molecular Cancer Therapeutics·2025
Abstract 7024: Discovery of highly selective, potent and orally bio-available SMARCA2 degraders
Cancer Research·2025
Abstract 7017: Discovery and development of a highly co-operative and potent pan-KRAS degrader
Cancer Research·2025
Abstract 7019: Identification of first-in-class paralog selective SMARCA4 degraders for treatment of hematological and prostate malignancies
Cancer Research·2025
Degrading SMARCA2/4 Relieves the Differentiation Block in AML Via Chromatin Alterations Affecting S100A8/9
Blood·2024
230 (PB218): Combining OP-3136, a KAT6 inhibitor, with endocrine therapy and CDK4/6 inhibitor enhances anti-tumor activity in ER+/HER2- breast cancer models
European Journal of Cancer·2024
P-042 SWASTH: Phase 1/2 Study of Ribrecabtagene Autoleucel, a BCMA–Directed CAR-T Cell Therapy, in Relapsed-Refractory Multiple Myeloma
Clinical Lymphoma Myeloma & Leukemia·2024
Targeting the mSWI/SNF complex in POU2F-POU2AF transcription factor-driven malignancies
Cancer Cell·2024· 39 citedOpen Access
Author Correction: Targeting SWI/SNF ATPases in enhancer-addicted prostate cancer
Nature·2024· 5 citedOpen Access
Abstract 2670: Development of novel anti-SIRPα/β dual antibody with single-agent phagocytosis activity
Cancer Research·2024
Abstract 6602: Targeting the SWI/SNF complex in POU2F-POU2AF transcription factor-driven malignancies
Cancer Research·2024
Abstract 6065: Identification and characterization of paralogue selective CBP degraders for potential use in cancer therapy
Cancer Research·2024
Abstract 6537: A novel CCR4 antagonist induces potent anti-tumor response through inhibition of Treg migration into the tumor microenvironment
Cancer Research·2024· 1 cited
Abstract 3303: Paralogue selective p300 degraders induce synthetic lethality in pre-clinical models of CBP-deficient and p300-dependent malignancies
Cancer Research·2024
Abstract 1703: SMARCA2/4 degraders relieve the differentiation block in AML via changes in chromatin looping and accessibility
Cancer Research·2024
Targeting the mSWI/SNF Complex in POU2F-POU2AF Transcription Factor-Driven Malignancies
2024· 9 citedOpen Access
page 1 of 13Next →

Frequent Co-authors

Michael M. Gottesman(9), Suresh V. Ambudkar(8), Ira Pastan(8), Christine A. Hrycyna(7), Subhendu Mukherjee(7), Pottayil G. Sasikumar(7), Saibal Dey(5), Paul Shabram(5), Narasimha Rao Krishnamurthy(5), Raghuveer Ramachandra(4), Anirudha Lakshminarasimhan(4), John A. Howe(4), Isabella Atencio(4), Leena K. Satyam(4), Dodheri S. Samiulla(4), Gerd Wohlfahrt(4), Susanta Samajdar(3), Anuradha Ramanathan(3), Amit A. Dhudashiya(3), Rashmi Nair(3)